{
    "abstractText": "Introduction: Dyslipidemia-hypertension proves to be a major risk factor for cardiovascular diseases. In order to achieve better adherence and cost-effectiveness than free equivalent combination therapies, a fixed-dose combination therapy with telmisartan (TEL), rosuvastatin calcium (ROS) and amlodipine besylate (AML) is required in this type of patients. Aim: A simple, selective and reproducible reverse phase high performance liquid chromatography (RP-HPLC) method has been developed and validated for estimation of telmisartan, rosuvastatin calcium, and amlodipine besylate in synthetic mixture. Materials and methods: Chromatographic separation was performed on a reversed-phase Luna C18 100\u00c5 column (250 mm \u00d7 4.6 mm i.d., particle size 5 \u03bc) using an isocratic elution of mobile phase consisting of methanol and acetonitrile (pH 3.5 adjusted by orthophosphoric acid) (60:40 v/v) at a flow rate of 1.0 ml/min. Results: Ultraviolet (UV) detection was performed at 242 nm and retention time of telmisartan, rosuvastatin calcium and amlodipine besylate was found to be 2.67, 4.70, and 7.44 min, respectively. The calibration curve was linear (correlation coefficient >0.999) in the selected range of analyte. Conclusions: The method was validated for accuracy, precision, linearity, limit of detection, limit of quantitation and ruggedness. The system suitability parameter, such as theoretical plate, asymmetry, and resolution between standard five replicate were well within the limits.",
    "authors": [
        {
            "affiliations": [],
            "name": "Rujuta P. Mistry"
        },
        {
            "affiliations": [],
            "name": "Chainesh Shah"
        },
        {
            "affiliations": [],
            "name": "Rakesh Jat"
        }
    ],
    "id": "SP:2f8162b4f38af6bb77415743ac9c34f06868d3c1",
    "references": [
        {
            "authors": [
                "J Elseena",
                "CN Anjana",
                "K Merlin"
            ],
            "title": "Telmisartan and rosuvastatin: a review on the analytical methods for the individual and combined dosage forms",
            "venue": "Int J Res Anal Rev",
            "year": 2020
        },
        {
            "authors": [
                "H Kaila",
                "A Aambasana",
                "S Thakkar"
            ],
            "title": "A new improved RP-HPLC method for assay of rosuvastatin calcium in tablets",
            "venue": "Indian J Pharm Sci",
            "year": 2010
        },
        {
            "authors": [
                "S Kumar",
                "B. Ram"
            ],
            "title": "Analytical method development and validation of amlodipine besylate in tablet dosage form",
            "venue": "J Drug Deliv Ther",
            "year": 2019
        },
        {
            "authors": [
                "V Chavhan",
                "R Lawande",
                "J Salunke"
            ],
            "title": "UV spectrophotometric method development and validation for telmisartan in bulk and tablet dosage form",
            "venue": "Asian J Pharm Clin Res",
            "year": 2013
        },
        {
            "authors": [
                "J Shen",
                "Z Jiao",
                "ZD Li"
            ],
            "title": "HPLC determination of telmisartan in human plasma and its application to a pharmacokinetic study",
            "venue": "Int J Pharm Sci Res",
            "year": 2005
        },
        {
            "authors": [
                "ML Surekha",
                "GK Swamy",
                "GL. Ashwini"
            ],
            "title": "Development and Validation of RP-HPLC method for the estimation of telmisartan in bulk and tablet dosage form",
            "venue": "Int J Drug Dev Res",
            "year": 2012
        },
        {
            "authors": [
                "Penfei LI",
                "Jinkai GU"
            ],
            "title": "Determination of telmisartan in human plasma by liquid chromatography - tandem mass spectrometry",
            "venue": "J Chromatogr B",
            "year": 2005
        },
        {
            "authors": [
                "P Mishra",
                "K. Shah"
            ],
            "title": "Simple UV spectrophotometric determination of rosuvastatin calcium in pure form and in pharmaceutical formulations",
            "venue": "J Chem",
            "year": 2009
        },
        {
            "authors": [
                "A Karunakaran",
                "V Subhash",
                "R Chinthala"
            ],
            "title": "Simultaneous estimation of rosuvastatin calcium and fenofibrate in bulk and in tablet dosage form by UV-spectrophotometry and RP-HPLC",
            "venue": "Stamford J Pharm Sci",
            "year": 2011
        },
        {
            "authors": [
                "BG Chaudhari",
                "NM Patel",
                "PB. Shah"
            ],
            "title": "Determination of simvastatin, pravastatin sodium and rosuvastatin calcium in tablet dosage forms by HPTLC",
            "venue": "Indian J Pharm Sci",
            "year": 2007
        },
        {
            "authors": [
                "AV Kasture",
                "R. Madhuri"
            ],
            "title": "Simulataneous UV-spectrophotometric method for the estimation of atenolol and amlodipine besylate in combined dosage form",
            "venue": "Indian J Pharm Sci",
            "year": 2006
        },
        {
            "authors": [
                "DA Shah",
                "KK Bhatt",
                "MB Shankar"
            ],
            "title": "RP-HPLC determination of atorvastatin calcium and amlodipine besylate combination in tablets",
            "venue": "Indian J Pharm Sci",
            "year": 2006
        },
        {
            "authors": [
                "PS Jain",
                "MK Patel",
                "SB Bari"
            ],
            "title": "Development and validation of HPTLC method for simultaneous determination of amlodipine besylate and metoprolol succinate in bulk and tablet dosage",
            "venue": "form. Indian J Pharm Sci",
            "year": 2012
        },
        {
            "authors": [
                "X Jin",
                "MH Kim",
                "KH Han"
            ],
            "title": "Efficacy and safety of co\u2010administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia",
            "venue": "J Clin Hypertens",
            "year": 2020
        },
        {
            "authors": [
                "M Son",
                "J Guk",
                "Y Kim"
            ],
            "title": "Pharmacokinetic interaction between rosuvastatin, telmisartan, and amlodipine in healthy male Korean subjects: a randomized, open-label, multiple-dose, 2-period crossover study",
            "venue": "Clin Ther",
            "year": 2016
        },
        {
            "authors": [
                "JFK Huber",
                "R Van der Linden",
                "E Ecker"
            ],
            "title": "Column switching in high pressure liquid chromatography",
            "venue": "J Chromatogr",
            "year": 1973
        },
        {
            "authors": [
                "KS Yun",
                "C Zhu",
                "JF. Parcher"
            ],
            "title": "Theoretical relationships between the void volume, mobile phase volume, retention volume, adsorption, and Gibbs free energy in chromatographic processes",
            "venue": "Anal Chem",
            "year": 1995
        },
        {
            "authors": [
                "Heinisch S",
                "Rocca JL"
            ],
            "title": "Effect of mobile phase composition, pH and buffer type on the retention of ionizable compounds in reversedphase liquid chromatography: application to method development",
            "venue": "J Chromatogr A",
            "year": 2004
        },
        {
            "authors": [
                "Chandran S",
                "Singh RSP"
            ],
            "title": "Comparison of various international guidelines for analytical method validation",
            "venue": "Pharmazie",
            "year": 2007
        },
        {
            "authors": [
                "P Kirtan",
                "KP Patel",
                "UK Chhalotiya"
            ],
            "title": "A new RP-HPLC method for simultaneous quantification of perindopril erbumine, indapamide, and amlodipine besylate in bulk and pharmaceutical dosage",
            "venue": "form. Future J Pharm Sci",
            "year": 2020
        },
        {
            "authors": [
                "D Kansara",
                "UK Chhalotiya",
                "HM Kachhiya"
            ],
            "title": "Development of TLC method for simultaneous estimation of novel combination of amlodipine besylate, rosuvastatin calcium, and fimasartan potassium in synthetic mixture",
            "venue": "J Chem Metrol",
            "year": 2020
        }
    ],
    "sections": [
        {
            "text": "103\nCopyright by authors. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.\nAim: A simple, selective and reproducible reverse phase high performance liquid chromatography (RP-HPLC) method has been developed and validated for estimation of telmisartan, rosuvastatin calcium, and amlodipine besylate in synthetic mixture.\nMaterials and methods: Chromatographic separation was performed on a reversed-phase Luna C18 100\u00c5 column (250 mm \u00d7 4.6 mm i.d., particle size 5 \u03bc) using an isocratic elution of mobile phase consisting of methanol and acetonitrile (pH 3.5 adjusted by orthophosphoric acid) (60:40 v/v) at a flow rate of 1.0 ml/min.\nResults: Ultraviolet (UV) detection was performed at 242 nm and retention time of telmisartan, rosuvastatin calcium and amlodipine besylate was found to be 2.67, 4.70, and 7.44 min, respectively. The calibration curve was linear (correlation coefficient >0.999) in the selected range of analyte.\nConclusions: The method was validated for accuracy, precision, linearity, limit of detection, limit of quantitation and ruggedness. The system suitability parameter, such as theoretical plate, asymmetry, and resolution between standard five replicate were well within the limits.\nKeywords accuracy, ICH guideline, mobile phase, precision, retention time.\n104\nFolia Medica I 2022 I Vol. 64 I No. 1"
        },
        {
            "heading": "INTRODUCTION",
            "text": "Telmisartan is chemically described as 2-(4- {[4-methyl6-(1-methyl-1H-1,3-benzodiazol-2-propyl-1H- 1,3benzodiazol-1-yl] methyl}phenyl) benzoic acid. It is used as an angiotensin II receptor antagonist (AT1) in the management of hypertension.1 It selectively antagonizes angiotensin II binding to the AT1 subtype receptors. It is commonly administered through the oral route.\nRosuvastatin calcium is chemically calcium: (E,3R,5S)-7-[4-(4-fluorophenyl)-2- [methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate. It belongs to a class of drugs called statins, which are employed in lowering hypercholesterolemia, its related conditions and preventing cardiovascular diseases.2\nAmlodipine besylate is chemically described as 3-ethyl-5-methyl (\u00b1)-2-[(2-aminoethox) methyl]-4-(2- chlorophenyl)-1, 4- dihydro-6-methyl-3, 5-pyridinedi carboxylate, mono benzene sulphonate. AML is a calcium channel blocker2, which inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes, thus decreasing the contractile process and hence dilating coronary and systemic arteries3.\nThe literature survey revealed that methods available for the determination of telmisartan are such as [UV]4, [HPLC]5, [RP-HPLC]6, and [Tandem mass spectrometry]7. The methods available for determination of rosuvastatin calcium are [UV]8, [RPHPLC]9, [HPTLC]10, etc. Similarly, for determination of ADB, the methods are [UV]11, [RP-HPLC]12, and [HPTLC]13. Many methods have been described in the literature for determination of telmisartan, rosuvastatin calcium, and amlodipine besylate individually and in combination with other drugs. No single method was reported for the estimation in the combined form."
        },
        {
            "heading": "AIM",
            "text": "The present work described a validated reverse phase HPLC method for determination of TEL, ROS, and AML in synthetic mixture used in the management of hypertension with dyslipidemia.14"
        },
        {
            "heading": "MATERIALS AND METHODS",
            "text": ""
        },
        {
            "heading": "Chemicals and materials",
            "text": "The raw materials for telmisartan and Rosuvastatin were received as gift sample from Dano Pharmacham Pvt.Ltd., Ankleswar. Amlodipine Besylate raw material was received as gift sample from Mccoy Drug Pvt. Ltd., Sachin. HPLC Grade Methanol was received from RANKEM and HPLC Grade Acetonitrile was received from E Merck Ltd. Membrane filter: 0.22 \u00b5m and Nylon membrane filters were received from RANKEM."
        },
        {
            "heading": "Instrumentation",
            "text": "Chromatographic analysis was carried out on liquid chromatography (UFLC Shimadzu Corporation, Japan) with LC-2010HT series binary pump system using a UV detector with Software CLASS \u2013VP (version 2.31) software to acquire and process the data. HPLC condition is given in Table 1."
        },
        {
            "heading": "Preparation of standard solution",
            "text": "1 ml of the standard stock solutions (1000 \u00b5g/ml) of all three drugs (TEL, ROS, and AML) was taken in a common volumetric flask diluted up to 10 ml with mobile phase - acetonitrile : methanol, pH=3.5 adjusted using orthophosphoric acid (60:40) to make the final concentration of 100:100:100 \u00b5g/ml.\nPreparation of a sample solution (assay procedure)\nIt was prepared as per the patent (telmisartan: 80 mg, rosuvastatin calcium: 20 mg, and amlodipine besylate: 10 mg) and talc quantity was sufficient. All the excipients were mixed in a 100-ml volumetric flask and sonicated for 15 min. The solution was filtered through Whattman filter paper no. 42. Finally, the solution concentrations were obtained as 800, 200, and 100 \u00b5g/ml for each of the drugs, respectively. From that pipette out 1 ml in a 10-ml volumetric flask and volume made up with mobile phase \u2013 methanol : acetonitrile (60:40 v/v) to make the final concentration of TEL (80 \u00b5g/ml), ROS (20 \u00b5g/ml), and AML (10 \u00b5g/ml) and recorded peak areas were noted for estimation of TEL, ROS and AML.15"
        },
        {
            "heading": "RESULTS AND DISCUSSIONS",
            "text": ""
        },
        {
            "heading": "Method validation",
            "text": ""
        },
        {
            "heading": "System suitability studies",
            "text": "The system suitability was evaluated by five replicate analyses of TEL, ROS, and AML mixture at concentrations of 80, 20, and 10 \u00b5g/ml of each drug, respectively. The column efficiency, resolution, and peak asymmetry were calculated for the standard solution. The results of system suitability and system precision were presented (Table 2).16-18"
        },
        {
            "heading": "Linearity and range",
            "text": "The linearity response was determined by analysing five independent levels of concentration in the range of 40-200 \u00b5g/ml for TEL, 10-50 \u00b5g/ml for ROS, and 5-25 \u00b5g/ml for AML.19-21 The results are presented in Table 3. A calibration curve was found to be linear with a regression coefficient (>0.99) (Fig. 1).\n105Folia Medica I 2022 I Vol. 64 I No. 1\nObserved values for system suitability test *(n=5)\n* n=5\nFigure 1. Calibration curve of telmisartan, rosuvastatin calcium, and amlodipine besylate."
        },
        {
            "heading": "Accuracy",
            "text": "The difference between theoretical added amount and practically achieved amount is called accuracy of analytical method. Accuracy was determined at three different levels \u2013 at 50%, 100%, and 150% of the target concentration in triplicate. The results are presented in Table 4.\nPrecision\nIntraday precision and interday precision\nThe precision of the developed method was assessed by analysing samples of the same batch with three combined solutions of TEL, ROS and AML in the concentration of 80,\n106\nFolia Medica I 2022 I Vol. 64 I No. 1\nINTRADAY PRECISION INTERDAY PRECISION\nDRUG Con. taken (\u03bcg/ml)\nMean Peak Area* %RSD DRUG Con. taken (\u03bcg/ml)\nMean Peak Area* %RSD\nTEL\n80 216788 0.67\nTEL\n80 206789 0.87\n120 288780 0.82 120 288685 0.80\n160 380998 0.56 160 374566 0.67\nROS\n20 145677 0.78\nROS\n20 155678 0.80\n30 312670 0.67 30 319080 0.69\n40 500134 0.21 40 526678 0.24\nAML\n10 298754 0.37\nAML\n10 289970 0.39\n15 354606 0.80 15 354567 0.81\n20 687888 0.88 20 698008 0.89\n120, and 160 \u03bcg/ml of TEL, 20, 30, and 40 \u03bcg/ml of ROS, and 10, 15, and 20 \u03bcg/ml of AML, respectively in three replicates (n=3) each on same day.22 The percentage of RSD value of the results corresponding to the peak area was expressed for intra-day precision. The precision of the developed method was assessed by analysing samples with three standard solutions of TEL, ROS, and AML similarly like above concentration respectively in three replicates (n=3) each on different day. The results are presented in Table 5. The results obtained were within 2% RSD.\nLimit of detection (LOD) and limit of quantification (LOQ)23,24\nThe LOD & LOQ were found to be 1.46 and 4.21 \u00b5g/ml for TEL, 0.54 and 1.63 \u00b5g/ml for ROS, and 0.78 and 2.01 \u00b5g/ml for AML, respectively.\nThe robustness of an analytical procedure is\u00a0a measure of its capacity to remain unaffected by small, but deliberate variations in method parameters\u00a0and provides an indication of its reliability during normal usage."
        },
        {
            "heading": "Robustness",
            "text": "As defined by The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), the robustness of an analytical procedure is\u00a0 a measure of its capacity to remain unaffected by small, but deliberate variations in method parameters. Robustness was performed by small variation in the chromatographic conditions and found to be unaffected by \u00b10.1 ml/min variation in flow rate of mobile phase, and \u00b10.1 variation in detection wavelength. These results are presented in Table 6."
        },
        {
            "heading": "Assay",
            "text": "The percentage assay of chromatogram analysis for bulk mixture of TEL, ROS, and AML were 99.98%, 100.21%, and 99.24%, respectively\nThe retention time of bulk mixture of TEL, ROS, and AML are 2.67 min, 4.70 min, and 7.44 min, respectively (Fig. 2).\n107Folia Medica I 2022 I Vol. 64 I No. 1"
        },
        {
            "heading": "CONCLUSIONS",
            "text": "A rational and valid attempt has been made for the development of telmisartan, rosuvastatin calcium, and amlodipine besylate in synthetic mixture. The accountability of the proposed method has been established by evaluating validation parameters as per ICH guidelines. The developed RP-HPLC methods are simple, economical, precise, and accurate for the simultaneous determination of telmisartan, rosuvastatin calcium, and amlodipine besylate in synthetic mixture."
        },
        {
            "heading": "Acknowledgements",
            "text": "The authors are thankful to M/s. Dano Pharmachem Pvt. Ltd. Ankleswar for providing gift sample of TEL and ROS, and to M/s. Mccoy Drug Pvt. Ltd., Sachin for providing gift sample of AML raw material. The authors would also like to thank Laxminarayan Dev College of Pharmacy and Shree Jagdishprashad Jablamer Tiberwala University for providing all facilities.\nREFERENCES 1. Elseena J, Anjana CN, Merlin K, et al. Telmisartan and rosuvastatin:\na review on the analytical methods for the individual and combined dosage forms. Int J Res Anal Rev 2020; 7(1):927\u201345. 2. Kaila H, Aambasana A, Thakkar S, et al. A new improved RP-HPLC method for assay of rosuvastatin calcium in tablets. Indian J Pharm Sci 2010; 72(5):592\u20138. 3. Kumar S, Ram B. Analytical method development and validation of amlodipine besylate in tablet dosage form. J Drug Deliv Ther 2019; 9(1):463\u20136. 4. Chavhan V, Lawande R, Salunke J, et al. UV spectrophotometric method development and validation for telmisartan in bulk and tablet dosage form. Asian J Pharm Clin Res 2013; 6(4):19\u201321. 5. Shen J, Jiao Z, Li ZD, et al. HPLC determination of telmisartan in human plasma and its application to a pharmacokinetic study. Int J Pharm Sci Res 2005; 60(6):418\u201320. 6. Surekha ML, Swamy GK, Ashwini GL. Development and Validation of RP-HPLC method for the estimation of telmisartan in bulk and tablet dosage form. Int J Drug Dev Res 2012; 4:200\u20135. 7. Penfei LI, Jinkai GU. Determination of telmisartan in human plasma by liquid chromatography - tandem mass spectrometry. J Chromatogr B 2005; 828(1):126\u20139.\n108\nFolia Medica I 2022 I Vol. 64 I No. 1\n8. Mishra P, Shah K. Simple UV spectrophotometric determination of rosuvastatin calcium in pure form and in pharmaceutical formulations. J Chem 2009; 6(1):89\u201392. 9. Karunakaran A, Subhash V, Chinthala R, et al. Simultaneous estimation of rosuvastatin calcium and fenofibrate in bulk and in tablet dosage form by UV-spectrophotometry and RP-HPLC. Stamford J Pharm Sci 2011; 4(1):58\u201363. 10. Chaudhari BG, Patel NM, Shah PB. Determination of simvastatin, pravastatin sodium and rosuvastatin calcium in tablet dosage forms by HPTLC. Indian J Pharm Sci 2007; 69(1):130\u20132. 11. Kasture AV, Madhuri R. Simulataneous UV-spectrophotometric method for the estimation of atenolol and amlodipine besylate in combined dosage form. Indian J Pharm Sci 2006; 68(3):394\u20136. 12. Shah DA, Bhatt KK, Shankar MB, et al. RP-HPLC determination of atorvastatin calcium and amlodipine besylate combination in tablets. Indian J Pharm Sci 2006; 68(6):796\u20139. 13. Jain PS, Patel MK, Bari SB, et al. Development and validation of HPTLC method for simultaneous determination of amlodipine besylate and metoprolol succinate in bulk and tablet dosage form. Indian J Pharm Sci 2012; 74(2):152\u20136. 14. Jin X, Kim MH, Han KH, et al. Efficacy and safety of co\u2010administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia. J Clin Hypertens 2020; 22(10):1835\u201345. 15. Son M, Guk J, Kim Y, et al. Pharmacokinetic interaction between rosuvastatin, telmisartan, and amlodipine in healthy male Korean subjects: a randomized, open-label, multiple-dose, 2-period crossover study. Clin Ther 2016; 38(8):1845\u201357. 16. Huber JFK, Van der Linden R, Ecker E, et al. Column switching in high pressure liquid chromatography. J Chromatogr 1973; 2:267\u201371. 17. Yun KS, Zhu C, Parcher JF. Theoretical relationships between the void volume, mobile phase volume, retention volume, adsorption, and Gibbs free energy in chromatographic processes. Anal Chem 1995; 4:613\u20139. 18. Heinisch S, Rocca JL. Effect of mobile phase composition, pH and buffer type on the retention of ionizable compounds in reversedphase liquid chromatography: application to method development. J Chromatogr A 2004; 1048:183\u201393. 19. International Conference on Harmonization of Technical Requirement for Registration of Pharmaceutical for Human use. Stability Testing of New Drug Substance and Products ICH Q2 (R1). 2003. 20. Chandran S, Singh RSP. Comparison of various international guidelines for analytical method validation. Pharmazie 2007; 62:4\u201314. 21. Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials. WHO Geneva 1997; 1(1):119\u201324. 22. Kirtan P, Patel KP, Chhalotiya UK, et al. A new RP-HPLC method for simultaneous quantification of perindopril erbumine, indapamide, and amlodipine besylate in bulk and pharmaceutical dosage form. Future J Pharm Sci 2020; 6:80. 23. Kansara D, Chhalotiya UK, Kachhiya HM, et al. Development of TLC method for simultaneous estimation of novel combination of amlodipine besylate, rosuvastatin calcium, and fimasartan potassium in synthetic mixture. J Chem Metrol 2020; 14:142\u201352. 24. Murtaza G, Akhtar Y, Mahmood T, et al. A novel UV-spectrophotometric method for simultaneous estimation of amlodipine and captopril. Pharm Chem J 2019; 52(11):952\u20138.\n109Folia Medica I 2022 I Vol. 64 I No. 1\n\u0420\u0430\u0437\u0440\u0430\u0431\u043e\u0442\u043a\u0430 \u0438 \u0432\u0430\u043b\u0438\u0434\u0430\u0446\u0438\u044f \u043c\u0435\u0442\u043e\u0434\u0430 RP-HPLC \u0434\u043b\u044f \u043e\u0434\u043d\u043e\u0432\u0440\u0435\u043c\u0435\u043d\u043d\u043e\u0439 \u043e\u0446\u0435\u043d\u043a\u0438 \u0442\u0435\u043b\u043c\u0438\u0441\u0430\u0440\u0442\u0430\u043d\u0430, \u0440\u043e\u0437\u0443\u0432\u0430\u0441\u0442\u0430\u0442\u0438\u043d\u0430 \u043a\u0430\u043b\u044c\u0446\u0438\u044f \u0438 \u0430\u043c\u043b\u043e\u0434\u0438\u043f\u0438\u043d\u0430 \u0431\u0435\u0437\u0438\u043b\u0430\u0442\u0430 \u0432 \u043a\u043e\u043c\u0431\u0438\u043d\u0430\u0446\u0438\u0438 \u0420\u0443\u0434\u0436\u0443\u0442\u0430 \u041f. \u041c\u0438\u0441\u0442\u0440\u04381, \u0427\u0430\u0439\u043d\u0435\u0448 \u0428\u0430\u04452, \u0420\u0430\u043a\u0435\u0448 \u0414\u0436\u0430\u04423 1 \u041a\u0430\u0444\u0435\u0434\u0440\u0430 \u043e\u0431\u0435\u0441\u043f\u0435\u0447\u0435\u043d\u0438\u044f \u043a\u0430\u0447\u0435\u0441\u0442\u0432\u0430, \u0423\u043d\u0438\u0432\u0435\u0440\u0441\u0438\u0442\u0435\u0442 \u0428\u0440\u0438 \u0414\u0436\u0430\u0433\u0434\u0438\u0448\u043f\u0440\u0430\u0441\u0430\u0434 \u0414\u0436\u0430\u0431\u0430\u0440\u043c\u0430\u043b \u0422\u0438\u0431\u0440\u0435\u0432\u0430\u043b\u0430, \u0412\u0438\u0434\u044f\u043d\u0430\u0433\u0430\u0440\u0438, \u0414\u0436\u0443\u043d\u0434\u0436\u0443\u043d\u0443, \u0411\u0430\u0440\u0443\u0445, \u0418\u043d\u0434\u0438\u044f 2 \u041a\u0430\u0444\u0435\u0434\u0440\u0430 \u0444\u0430\u0440\u043c\u0430\u0446\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0445 \u043d\u0430\u0443\u043a, \u0424\u0430\u0440\u043c\u0430\u0446\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0438\u043d\u0441\u0442\u0438\u0442\u0443\u0442 \u201e\u0421\u0438\u0433\u043c\u0430\u201c, \u0412\u0430\u0434\u043e\u0434\u0430\u0440\u0430, \u0418\u043d\u0434\u0438\u044f 3 \u041a\u0430\u0444\u0435\u0434\u0440\u0430 \u0444\u0430\u0440\u043c\u0430\u0446\u0438\u0438, \u0423\u043d\u0438\u0432\u0435\u0440\u0441\u0438\u0442\u0435\u0442 \u0428\u0440\u0438 \u0414\u0436\u0430\u0433\u0434\u0438\u0448\u043f\u0440\u0430\u0441\u0430\u0434 \u0414\u0436\u0430\u0431\u0430\u0440\u043c\u0430\u043b \u0422\u0438\u0431\u0440\u0435\u0432\u0430\u043b\u0430, \u0412\u0438\u0434\u044f\u043d\u0430\u0433\u0430\u0440\u0438, \u0414\u0436\u0443\u043d\u0434\u0436\u0443\u043d\u0443, \u0420\u0430\u0434\u0436\u0430\u0441\u0442\u0430\u043d, \u0411\u0430\u0440\u0443\u0445, \u0418\u043d\u0434\u0438\u044f\n\u0410\u0434\u0440\u0435\u0441 \u0434\u043b\u044f \u043a\u043e\u0440\u0440\u0435\u0441\u043f\u043e\u043d\u0434\u0435\u043d\u0446\u0438\u0438: \u0420\u0443\u0434\u0436\u0443\u0442\u0430 \u041f. \u041c\u0438\u0441\u0442\u0440\u0438, \u041a\u0430\u0444\u0435\u0434\u0440\u0430 \u043e\u0431\u0435\u0441\u043f\u0435\u0447\u0435\u043d\u0438\u044f \u043a\u0430\u0447\u0435\u0441\u0442\u0432\u0430, \u0423\u043d\u0438\u0432\u0435\u0440\u0441\u0438\u0442\u0435\u0442 \u0428\u0440\u0438 \u0414\u0436\u0430\u0433\u0434\u0438\u0448\u043f\u0440\u0430\u0441\u0430\u0434 \u0414\u0436\u0430\u0431\u0430\u0440\u043c\u0430\u043b \u0422\u0438\u0431\u0440\u0435\u0432\u0430\u043b\u0430, \u0412\u0438\u0434\u044f\u043d\u0430\u0433\u0430\u0440\u0438, \u0414\u0436\u0443\u043d\u0434\u0436\u0443\u043d\u0443, \u0420\u0430\u0434\u0436\u0430\u0441\u0442\u0430\u043d \u2013 333001, \u0410.1/36, \u0443\u043b. \u2116 8, \u041d\u0430\u0440\u0430\u044f\u043d \u041a\u0443\u043d\u0436 \u0412\u0438\u0445\u0430\u0440 \u0421\u043e\u0441\u0430\u0439\u0435\u0442\u0438, \u0432 \u0440\u0430\u0439\u043e\u043d\u0435 \u0413.\u041d.\u0424.\u041a., \u0411\u0430\u0440\u0443\u0445-392015, \u0418\u043d\u0434\u0438\u044f; E-mail: rujuprajapati@gmail.com\n\u0414\u0430\u0442\u0430 \u043f\u043e\u043b\u0443\u0447\u0435\u043d\u0438\u044f: 12 \u0444\u0435\u0432\u0440\u0430\u043b\u044f 2021 \u2666 \u0414\u0430\u0442\u0430 \u043f\u0440\u0438\u0435\u043c\u043a\u0438: 17 \u043c\u0430\u0440\u0442\u0430 2021 \u2666 \u0414\u0430\u0442\u0430 \u043f\u0443\u0431\u043b\u0438\u043a\u0430\u0446\u0438\u0438: 28 \u0444\u0435\u0432\u0440\u0430\u043b\u044f 2022\n\u041e\u0431\u0440\u0430\u0437\u0435\u0446 \u0446\u0438\u0442\u0438\u0440\u043e\u0432\u0430\u043d\u0438\u044f: Mistry RP, Shah C, Jat R. RP-HPLC method development and validation for simultaneous estimation of telmisartan, rosuvastatin calcium, and amlodipine besylate in combination. Folia Med (Plovdiv) 2022;64(1):103-9. doi: 10.3897/ folmed.64.e64339.\n\u0420\u0435\u0437\u044e\u043c\u0435 \u0412\u0432\u0435\u0434\u0435\u043d\u0438\u0435: \u0414\u0438\u0441\u043b\u0438\u043f\u0438\u0434\u0435\u043c\u0438\u044f-\u0433\u0438\u043f\u0435\u0440\u0442\u0435\u043d\u0437\u0438\u044f \u044f\u0432\u043b\u044f\u0435\u0442\u0441\u044f \u043e\u0441\u043d\u043e\u0432\u043d\u044b\u043c \u0444\u0430\u043a\u0442\u043e\u0440\u043e\u043c \u0440\u0438\u0441\u043a\u0430 \u0440\u0430\u0437\u0432\u0438\u0442\u0438\u044f \u0441\u0435\u0440\u0434\u0435\u0447\u043d\u043e-\u0441\u043e\u0441\u0443\u0434\u0438\u0441\u0442\u044b\u0445 \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u0439. \u0414\u043b\u044f \u0434\u043e\u0441\u0442\u0438\u0436\u0435\u043d\u0438\u044f \u043b\u0443\u0447\u0448\u0435\u0439 \u043f\u0440\u0438\u0432\u0435\u0440\u0436\u0435\u043d\u043d\u043e\u0441\u0442\u0438 \u0438 \u044d\u043a\u043e\u043d\u043e\u043c\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u044d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u0438 \u043f\u043e \u0441\u0440\u0430\u0432\u043d\u0435\u043d\u0438\u044e \u0441 \u0431\u0435\u0441\u043f\u043b\u0430\u0442\u043d\u043e\u0439 \u044d\u043a\u0432\u0438\u0432\u0430\u043b\u0435\u043d\u0442\u043d\u043e\u0439 \u043a\u043e\u043c\u0431\u0438\u043d\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u043e\u0439 \u0442\u0435\u0440\u0430\u043f\u0438\u0435\u0439 \u0443 \u044d\u0442\u043e\u0433\u043e \u0442\u0438\u043f\u0430 \u043f\u0430\u0446\u0438\u0435\u043d\u0442\u043e\u0432 \u0442\u0440\u0435\u0431\u0443\u0435\u0442\u0441\u044f \u043a\u043e\u043c\u0431\u0438\u043d\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u0430\u044f \u0442\u0435\u0440\u0430\u043f\u0438\u044f \u0441 \u0444\u0438\u043a\u0441\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u044b\u043c\u0438 \u0434\u043e\u0437\u0430\u043c\u0438 \u0442\u0435\u043b\u043c\u0438\u0441\u0430\u0440\u0442\u0430\u043d\u0430 (TEL), \u0440\u043e\u0437\u0443\u0432\u0430\u0441\u0442\u0430\u0442\u0438\u043d\u0430 \u043a\u0430\u043b\u044c\u0446\u0438\u044f (ROS) \u0438 \u0430\u043c\u043b\u043e\u0434\u0438\u043f\u0438\u043d\u0430 \u0431\u0435\u0437\u0438\u043b\u0430\u0442\u0430 (ADB).\n\u0426\u0435\u043b\u044c: \u0420\u0430\u0437\u0440\u0430\u0431\u043e\u0442\u0430\u043d \u0438 \u0443\u0442\u0432\u0435\u0440\u0436\u0434\u0451\u043d \u043f\u0440\u043e\u0441\u0442\u043e\u0439 \u043c\u0435\u0442\u043e\u0434 \u0441\u0435\u043b\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0439 \u0432\u044b\u0441\u043e\u043a\u043e\u044d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0439 \u0436\u0438\u0434\u043a\u043e\u0441\u0442\u043d\u043e\u0439 \u0445\u0440\u043e\u043c\u0430\u0442\u043e\u0433\u0440\u0430\u0444\u0438\u0438 \u0441 \u043e\u0431\u0440\u0430\u0449\u0451\u043d\u043d\u043e\u0439 \u0444\u0430\u0437\u043e\u0439 (RP-HPLC) \u0434\u043b\u044f \u043e\u0446\u0435\u043d\u043a\u0438 \u0442\u0435\u043b\u043c\u0438\u0441\u0430\u0440\u0442\u0430\u043d\u0430, \u0440\u043e\u0437\u0443\u0432\u0430\u0441\u0442\u0430\u0442\u0438\u043d\u0430 \u043a\u0430\u043b\u044c\u0446\u0438\u044f \u0438 \u0431\u0435\u0437\u0438\u043b\u0430\u0442\u0430 \u0430\u043c\u043b\u043e\u0434\u0438\u043f\u0438\u043d\u0430 \u0432 \u0441\u0438\u043d\u0442\u0435\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0445 \u0441\u043c\u0435\u0441\u044f\u0445.\n\u041c\u0430\u0442\u0435\u0440\u0438\u0430\u043b\u044b \u0438 \u043c\u0435\u0442\u043e\u0434\u044b: \u0425\u0440\u043e\u043c\u0430\u0442\u043e\u0433\u0440\u0430\u0444\u0438\u0447\u0435\u0441\u043a\u043e\u0435 \u0440\u0430\u0437\u0434\u0435\u043b\u0435\u043d\u0438\u0435 \u043d\u0430 \u043a\u043e\u043b\u043e\u043d\u043a\u0435 \u0441 \u043e\u0431\u0440\u0430\u0449\u0451\u043d\u043d\u043e\u0439 \u0444\u0430\u0437\u043e\u0439 Luna C18 100\u00c5 (250 \u043c\u043c \u00d7 4.6 \u043c\u043c i.d, \u0440\u0430\u0437\u043c\u0435\u0440 \u0447\u0430\u0441\u0442\u0438\u0446 5 \u03bc) \u043f\u0440\u043e\u0432\u043e\u0434\u0438\u043b\u0438 \u0438\u0437\u043e\u043a\u0440\u0430\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u043c \u044d\u043b\u044e\u0438\u0440\u043e\u0432\u0430\u043d\u0438\u0435\u043c \u043f\u043e\u0434\u0432\u0438\u0436\u043d\u043e\u0439 \u0444\u0430\u0437\u044b, \u0441\u043e\u0441\u0442\u043e\u044f\u0449\u0435\u0439 \u0438\u0437 \u043c\u0435\u0442\u0430\u043d\u043e\u043b\u0430 \u0438 \u0430\u0446\u0435\u0442\u043e\u043d\u0438\u0442\u0440\u0438\u043b\u0430 (pH 3.5 \u0434\u043e\u0432\u043e\u0434\u0438\u043b\u0438 \u043e\u0440\u0442\u043e\u0444\u043e\u0441\u0444\u043e\u0440\u043d\u043e\u0439 \u043a\u0438\u0441\u043b\u043e\u0442\u043e\u0439) (60:40 v/v), \u0441\u043e \u0441\u043a\u043e\u0440\u043e\u0441\u0442\u044c\u044e \u043f\u043e\u0442\u043e\u043a\u0430 1.0 \u043c\u043b/\u043c\u0438\u043d.\n\u0420\u0435\u0437\u0443\u043b\u044c\u0442\u0430\u0442\u044b: \u0423\u043b\u044c\u0442\u0440\u0430\u0444\u0438\u043e\u043b\u0435\u0442\u043e\u0432\u0443\u044e (UV) \u0434\u0435\u0442\u0435\u043a\u0446\u0438\u044e \u043f\u0440\u043e\u0432\u043e\u0434\u0438\u043b\u0438 \u043f\u0440\u0438 242 \u043d\u043c, \u0430 \u0432\u0440\u0435\u043c\u044f \u0443\u0434\u0435\u0440\u0436\u0438\u0432\u0430\u043d\u0438\u044f \u0442\u0435\u043b\u043c\u0438\u0441\u0430\u0440\u0442\u0430\u043d\u0430, \u0440\u043e\u0437\u0443\u0432\u0430\u0441\u0442\u0430\u0442\u0438\u043d\u0430 \u043a\u0430\u043b\u044c\u0446\u0438\u044f \u0438 \u0430\u043c\u043b\u043e\u0434\u0438\u043f\u0438\u043d\u0430 \u0431\u0435\u0437\u0438\u043b\u0430\u0442\u0430 \u0441\u043e\u0441\u0442\u0430\u0432\u043b\u044f\u043b\u043e 2.67, 4.70 \u0438 7.44 \u043c\u0438\u043d \u0441\u043e\u043e\u0442\u0432\u0435\u0442\u0441\u0442\u0432\u0435\u043d\u043d\u043e. \u041a\u0430\u043b\u0438\u0431\u0440\u043e\u0432\u043e\u0447\u043d\u0430\u044f \u043a\u0440\u0438\u0432\u0430\u044f \u0431\u044b\u043b\u0430 \u043b\u0438\u043d\u0435\u0439\u043d\u043e\u0439 (\u043a\u043e\u044d\u0444\u0444\u0438\u0446\u0438\u0435\u043d\u0442 \u043a\u043e\u0440\u0440\u0435\u043b\u044f\u0446\u0438\u0438 > 0.999).\n\u0417\u0430\u043a\u043b\u044e\u0447\u0435\u043d\u0438\u0435: \u041c\u0435\u0442\u043e\u0434 \u0431\u044b\u043b \u0432\u0430\u043b\u0438\u0434\u0438\u0440\u043e\u0432\u0430\u043d \u043d\u0430 \u043f\u0440\u0430\u0432\u0438\u043b\u044c\u043d\u043e\u0441\u0442\u044c, \u043f\u0440\u0435\u0446\u0438\u0437\u0438\u043e\u043d\u043d\u043e\u0441\u0442\u044c, \u043b\u0438\u043d\u0435\u0439\u043d\u043e\u0441\u0442\u044c, \u043f\u0440\u0435\u0434\u0435\u043b \u043e\u0431\u043d\u0430\u0440\u0443\u0436\u0435\u043d\u0438\u044f, \u043f\u0440\u0435\u0434\u0435\u043b \u043a\u043e\u043b\u0438\u0447\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0433\u043e \u043e\u043f\u0440\u0435\u0434\u0435\u043b\u0435\u043d\u0438\u044f \u0438 \u0441\u0442\u0430\u0431\u0438\u043b\u044c\u043d\u043e\u0441\u0442\u044c. \u041f\u0430\u0440\u0430\u043c\u0435\u0442\u0440\u044b \u043f\u0440\u0438\u0433\u043e\u0434\u043d\u043e\u0441\u0442\u0438 \u0441\u0438\u0441\u0442\u0435\u043c\u044b, \u0442\u0430\u043a\u0438\u0435 \u043a\u0430\u043a \u0442\u0435\u043e\u0440\u0435\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u043f\u043b\u0438\u0442\u044b, \u0430\u0441\u0438\u043c\u043c\u0435\u0442\u0440\u0438\u044f \u0438 \u0440\u0430\u0437\u043b\u043e\u0436\u0435\u043d\u0438\u0435 \u0432 \u0441\u0442\u0430\u043d\u0434\u0430\u0440\u0442\u043d\u043e\u0439 \u043f\u044f\u0442\u0438\u043a\u0440\u0430\u0442\u043d\u043e\u0439 \u043f\u043e\u0432\u0442\u043e\u0440\u043d\u043e\u0441\u0442\u0438, \u043d\u0430\u0445\u043e\u0434\u0438\u043b\u0438\u0441\u044c \u0432 \u043f\u0440\u0435\u0434\u0435\u043b\u0430\u0445 \u043d\u043e\u0440\u043c\u044b.\n\u041a\u043b\u044e\u0447\u0435\u0432\u044b\u0435 \u0441\u043b\u043e\u0432\u0430 \u0442\u043e\u0447\u043d\u043e\u0441\u0442\u044c, \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 ICH, \u043f\u043e\u0434\u0432\u0438\u0436\u043d\u0430\u044f \u0444\u0430\u0437\u0430, \u043f\u0440\u0435\u0446\u0438\u0437\u0438\u043e\u043d\u043d\u043e\u0441\u0442\u044c, \u0432\u0440\u0435\u043c\u044f \u0443\u0434\u0435\u0440\u0436\u0438\u0432\u0430\u043d\u0438\u044f"
        }
    ],
    "title": "RP-HPLC Method Development and Validation for Simultaneous Estimation of Telmisartan, Rosuvastatin Calcium and Amlodipine Besylate in Combination",
    "year": 2022
}